The diseases of the peripheral nerves are quite common and diversified, are directly related to several factors, ranging from the imbalance related to good nutrition and adequate needs of nutrients, going to the injuries caused by drugs or mechanisms external to the human organism. Diabetes is a complex syndrome that affects and kills millions of people worldwide. We demonstrated through the experimental model of diabetes using STZ@ in single intraperitoneal dose of 60 mg / kg, that both a purely motor nerve can be directly affected as well as a special afferent nerve (cranial nerve), this comparison showed us that there is a possibility of having a new type of mixed type neuropathy, this may be related to the amount of the dose involved, such as the time of disease progression, but more studies need to be done for definitive confirmation. We can extrapolate the original results to understand the mechanisms of diabetes in humans, although it does not yet have an experimental model of type II diabetes, more related to eating disorders, the STZ application simulates the effects of type I or insulin dependent diabetes, with more serious and deleterious effects mainly the more distal portions of the nerves. Prevention and food control are very important, especially those related to the mechanisms that involve carbohydrate metabolism and its peripheral resistance. The original results commented here are relevant for the continuous study of this serious but old illness, but quite current in the medical and therapeutic clinic.
Introduction
Nearly 387 million people have diabetes worldwide, and this epidemic disease continues to rise at an alarming rate, being expected 552 million by 2030. [1, 2, 11, 14] Type 2 diabetes mellitus (T2DM) accounts for 95% of diagnosed diabetes, [2, 3] and its complications, including heart disease and stroke, result in significant morbidity and mortality, representing the first and fourth most common causes of death, respectively, in the U.S. [2, 3] Diabetes mellitus (DM) is the most common metabolic disease with a high prevalence rate in human society that eventually leads to the peripheral nervous system complications in a great number of patients. It is a chronic metabolic disorder that leads to long-term complications affecting some sites such as heart, kidney, retina, vessels and peripheral nerves. [4, 5, 10] Peripheral neuropathy is one of the common complications of diabetes which in turn increases the risk of other diabetes complications such as foot ulcers and amputation. [6, 7, 10] Almost more than half of diabetic patients suffer from different forms of neuropathy after passing 1-2 decades of their diseases. [8, 10] Abnormalities of polyol pathway and defects of protein kinase C metabolism which cause nerve demyelination have also been described in diabetic peripheral neuropathy. [9, 10] Based on these mechanisms of injury, various prevention and treatment strategies have been already suggested and are under investigation. [10] As mentioned before, peripheral neuropathies are a major cause of morbidity in patients with diabetes mellitus, affecting as many as 50% of patients with diabetes. [12, 14] They can cause acute and chronic neuropathic pain, hyperalgesia and impaired nerve conduction velocities, which can cause significant morbidity of these patients and affect their daily activities. [13, 14] There are two main types of DM. Type 1 DM (T1DM) results from the body's failure to produce insulin and type 2 DM (T2DM) results from insulin resistance, where cells fail to use insulin properly, sometimes combined with an absolute insulin deficiency. An increase in blood glucose levels represents a recognized diagnostic criterion for diabetes. [15] The best predictor of T2DM macrovascular complications is the preceding presence of microvascular complications, particularly diabetic polyneuropathy (DPN) and diabetic nephropathy (DN). [2] DPN consists of demyelization and axonal degeneration of peripheral nerves, [16] , leading to slowing of nerve conduction velocity and reduction of the amplitude of the compound muscle and sensory nerve action potentials. [16, 23] These features of diabetic polyneuropathy are observed in human diabetes [16, 24] and in experimentally induced diabetic animals. [17] [18] [19] [20] [21] [22] [23] DPN is one of the main complications of diabetes, which may impair the peripheral nerve regeneration. Though the causes for failed regeneration in diabetic peripheral nerves are not completely elucidated, possible etiopathologies have been reported, such as structural changes in peripheral blood vessels and reductions in blood flow, [25, 54] delays in recruitment of macrophages to clean degrading myelin in injured peripheral nerve fibers, [26, 54] and reductions in neurotrophic supports for nerve tissue regeneration. [27, 54] DPN is not a single entity, but encompasses several neuropathic syndromes, including sensory and motor defects. A wide variety of sensorimotor symptoms which affects approximately 50% of diabetic patients is presented by patients with DPN. Changes in the neural circuits may occur in the early stages in diabetes and are implicated in the development of DPN. [28] Early physiological disorders such as nerve conduction slowing and sensory loss can be used to diagnose and stage diabetic neuropathy, [29, 34] and may predict the onset of degenerative changes in neurons, Schwann cells and blood vessels. Nerve biopsy studies have described segmental demye-lination and axonal degeneration of large fibers as common features of nerve pathology, [30, 34] while the use of skin biopsies and corneal confocal microscopy has emphasized the early damage of small sensory fibers terminals. [ 
Methods
Despite considerable researches on DPN, evidence for pathophysiological changes in the nervous systems underlying the impairment of motor function still lacks neurostructural evidence. Previous studies have focused on the role of peripheral nerves in DPN. Increasing evidence now indicates that the onset of DPN might be in all levels of the nervous system, including both the Peripheral Nervous System (PNS) and the Central Nervous System (CNS). [28, 35, 36, 39] Although the involvement of both PNS and CNS in DPN has previously been recognized, the underlying mechanisms remain poorly understood, particularly in the changes of the neural circuits between spinal nerves and spinal cord via the Dorsal Root Ganglia (DRG) and ventral root. Thus, investigating the alterations in the neural circuits is essential for understanding the development of the sensory and motor defects in DPN. It is important remember that the spinal nerves conduct mixed signals, including sensory and motor information from nerve endings in the PNS, [28, 37] And finally, that the various types of DRG neurons send their central axonal processes to different parts of the spinal dorsal horn in the CNS. [28, 37, 38] Several morphometric studies have demonstrated abnormalities of the myelinated and unmyelinated fibers in painful DPN. [15, 39, 40, 41, 42] . Equally, a significant loss in dermal fiber density was observed in preclinical models of diabetes. [15] Besides, the mechanical response properties of spinal neurons have been shown to be altered in different models of neuropathic pain, including DPN. [15, 43, 44] Results have shown that the neuronal basis of diabetes-induced neuropathic pain might differ across models. This demonstrates the complexity of the neuronal reorganization following hyperglycemiainduced neuronal damage and the resulting challenge for an effective treatment of diabetes-based neuropathic pain. [15] Different models for diabetic neuropathy in the rat have demonstrated distinct response properties of spinal wide dynamic range (WDR) neurons. This specificity in electrophysiological properties of WDR neurons for every investigated model might reflect differences in the pathological mechanisms in pain transmission and also suggest substantial differences underlying diabetes-induced neuropathic pain in T1DM and T2DM, as well as between chemicallyinduced and genetically determined diabetic rats. These differences are most likely due to a variety in metabolic changes, pathology, disease progression as well as severity and duration of diabetes. It can be assumed that, depending on the severity and duration of diabetes, it is the degree of spinal reorganization, due to the degeneration of small afferents, for example, which leads to the deafferentation of spinal neurons and the abnormal branching of A-b fibers. [16, 45, 47] Moreover, the anatomical framework of the spinal cord allows the transfer of specific inputs to localized subsets of dorsal horn neurons. This allows the separation in signal transduction pathways for low-intensity stimuli and noxious stimuli. The structural reorganization on the level of the spinal cord might contribute to the development of the pain. [15, 45, 46] The different mechanisms involved in different pain sensations are still poorly understood. Especially in a complex and diverse disease as DPN, the plastic reorganization processes of the somatosensory system along the pain pathway need further detailed investigation. It was detected complex alterations in spinal neuronal response properties of hyperglycemic rats, which varied significantly depending on stimulus force and quality. The electrophysiological technique allows a very detailed qualitative characterization of neuronal hyperexcitability, in specific diabetes models that complement the behavioral findings. These data reveal that specific neuronal properties can be associated with behavioral sensory abnormalities measured by evoked response studies in conscious rats. [15] Pharmacological 
Results
The emerging clinical recognition of multiple risk factors associated with diabetic neuropathy has not been widely explored in animal models, where a reductionist approach has largely been adopted and a glucocentric view of pathogenic mechanisms has historically dominated [34, 55] . This approach is consistent with the primary risk factors for human diabetic neuropathy and the widely studied streptozotocin (STZ) model of type 1 diabetes replicates a number of features of diabetic neuropathy such as large fiber conduction slowing, sensory dysfunction and depletion of unmyelinated epidermal nerve fibers in the skin [34, 56, 57] STZdiabetic rodents are less successful at modeling the degenerative pathology of myelinated fibers. The most widely and consistently reported structural disorder in nerve trunks of STZ-diabetic rats is reduced axonal caliber of myelinated fibers [20, 35, 58, 59 ] while degenerative pathology occurs in the most distal nerves of STZ-diabetic mice only after many months of hyperglycemia. [34, 60] The absence of more dramatic nerve pathology is frequently attributed to the relatively short durations of hyperglycemia attainable in rodent models of diabetes. Direct investigation of the pathogenesis of segmental demyelination has been particularly impeded by the absence of Schwann cell and myelin pathology in the common models of diabetic neuropathy, and a considerable leap of faith is necessary when attempting to translate therapeutics from preclinical models to clinical trials. [34] Simalary to Gregory JA et al [34], we conducted a small experiment in order to show the degenerative pathology in distal nerves of STZ-diabetic induced [4] rats caused by the hyperglycemia. We used 12 male Wistar rats (n=12) at 42 days of age. They were induced to become diabetic with streptozotocin (STZ) [4] . Half of these animals (n=6) were fasted for 12 hours prior to being injected intraperitoneally with STZ (60 mg/kg) in a single dose. Control animals (n=6) received vehicle. Ten weeks after STZ injection the animals were perfused intracardially with Karnovsky solution. Right and left sciatic nerves were dissected and processed for epoxy resin embedding. Samples were imaged with a transmission electron microscope. Compare the control group nerves (Figure 1 ) with nerves of STZdiabetic induced rats (Figure 2) . These results were presented at the Expeirmental Biology Congress in Boston, USA, 2013.
Although diabetic neuropathy more commonly affects the peripheral nerves [35, 61] , or the optic nerve, and the autonomic fibers, hyperglycemia can also cause damage to other cranial nerves, such as the vestibulocochlear, shown by us in Figure 3 .
Schwann cell metabolism is certainly compromised by diabetes, [34, 61, 70] as indicated by depletion of nerve ciliary neurotrophic factor (CNTF) levels, [34, 62, 63] but myelin thickness, structure and ultrastructure are preserved when viewed in appropriately fixed tissue. Speculation as to why demyelination does not develop in diabetic rodents has frequently evoked the short absolute duration of exposure to diabetes in rats when compared to humans. [3] Diabetic rats develop slowing conduction on large fiber within weeks of onset of hyperglycemia that is initially reversible and has a metabolic pathogenesis. [35, 65, 66] A reduction in axonal caliber can be detected after 2-3 months of diabetes and contributes to progressive conduction slowing [34, 
Figure 2 A-F:
Representative electron-micrographs of the sciatic nerve of chronic STZ-induced diabetic rats.
A-B) Asterisks show axonal atrophy of large myelinated fibers and arrows show fibroblast profiles in A and fibroblast nucleus in B. x4,000. C) Suggestive image of a macrophage in the endoneurium, involving an unmyelinated fibers with their pseudopods. x4,000. In large magnification, the insertion in the center shows a pseudopod involving an unmyelinated fiber and a giant mitochondria shown by the white arrow. x27,000. D) Note the thin myelinated fibers showing signs of demyelination. x5,000. E) Another thin fiber demyelination image x5,000. F) Note in high magnification, a thin fiber demyelination (arrowhead) and the presence of a vacuole in the myelin sheath. x20,000. Acute nerve conduction velocities (NCV) slowing reported in other STZ-diabetic rat strains has been attributed to nerve ischemic hypoxia. [35, 71] It is notable that reductions in nerve blood flow (23 %) and conductance (20 %) after 6 months of STZinduced diabetes in WKY rats were substantially less than the 50 % decrease widely reported to occur following 2-4 weeks of diabetes in other strains using a variety of techniques. [34, [71] [72] [73] Reduced nerve blood flow after 6 months of diabetes in WKY rats was associated with a 29 % reduction in endoneurial blood vessel number. A slowly developing vasculopathy may contribute to reduced nerve blood flow in this strain. In general, STZ-diabetic WKY rats lacked the dramatic early nerve conduction slowing reported in other strains and displayed a slowly evolving impairment of conduction accompanied by loss of endoneurial blood vessels and reduced axonal radial growth. [34] SHR rats are hyperactive, [36, 74] and findings of reduced body weight and plasma insulin levels compared to WKY rats were consistent with prior reports. [34, 75, 76] SHR rats also showed progressively developing NCV deficits and attenuated axonal radial growth in the sciatic and sural nerves, without myelinated fiber loss or any change in fiber density. These features have been previously reported, [34, 77] along with generalized myelin thinning in formalin-fixed paraffin embedded sections. [34] Axons with disproportionately thin myelin sheaths were observed, while not sufficiently frequent to impact the average myelin thickness of all fibers in the nerve cross section, and they were more frequent in nerves from SHR rats than in age-matched WKY rats. Identification of supernumerary Schwann cell processes encircling thinly myelinated fibers reflects demyelination and subsequent remyelination. [34, 78, 79] Similar profiles are seen in nerve from diabetic patients [34, 67, 68] and can cause conduction slowing independent of axonopathy. [34, 80] Although the proportion of thinly myelinated fibers was low, each cross section analyzed illustrates one of approximately 50 Schwann cells that myelinate an axon along its length, assuming a nerve of 5 cm length and an intermodal distance of 1 mm. [34, 81] Myelin disorders are equally infrequent in cross sections of nerves from patients with neuropathy. [34, 80] It is not clear yet if myelin thinning persists along the entire length of occasional axons or if it is intermittently segmental along the length of many fibers. If the latter occurs, up to 10 % of all fibers within the sciatic nerve could be affected at some position (0.2 % in one crosssection x 50 potential internodes). Teased fiber studies may resolve this issue. Early NCV slowing in SHR rats may reflect segmental demyelination and partial remyelination, whereas the later period of attenuated NCV increase also includes a contribution from restricted axonal maturation. The findings support the suggestion that hypertension can promote peripheral neuropathy and serve as an independent risk factor for neuropathy in diabetic patients. [34, [82] [83] [84] [85] [86] Current murine data suggest that both elevated cholesterol and obesity may be particularly instrumental in inciting nervous system damage. Some authors contend that dyslipidemia and visceral adiposity in males form a network with insulin resistance, hypertension, and hyperglycemia to injure the peripheral nervous system, particularly myelinated large fibers. These murine data support that this network of metabolic impairments activates detrimental feed-forward cycles of local and systemic oxidative stress and dysregulated energy homeostasis with local mitochondrial dysfunction and inflammation, thus resulting in neural injury and DPN. Corroborating this idea, there are some clinical studies showing that dyslipidemiais strongly correlated with DPN [2, 87] and that lowering cholesterol, not glycemia, is significantly associated with decreasing lower-extremity amputations among patients with diabetes [2, 88] .
In summary, the glycemic control alone is not sufficient to ameliorate injury to large myelinated fibers in murine models of T2DM and DPN, likely because of the persistence of hypercholesterolemia as well as local neural dysfunctional lipoprotein signaling. These findings along with similar results in several large clinical trials in patients with T2DM and DPN collectively suggest that treatment of the metabolic syndrome as a whole and not just hyperglycemia is required to effectively target DPN in T2DM. [2] 
Conclusion
Impaired myelinated axon population of peripheral nerves as a consequence of regenerative failure has been clearly seen in the rat model of diabetes. [54, 89, 90] It could be caused by slow infiltration of endoneurial macrophages, delaying Wallerian degeneration and subsequent nerve regeneration. Another possibility that the regenerative deficit is related to decreased action of vasoactive neuropeptides such as calcitonin gene-related peptide (CGRP) in diabetics which may render an ischaemic environment in nerve microvessels following nerve injury. [26, 54] Percutaneous electrical stimulation (ES) of 1mA or above was suggested as possible inductor of a transient rise in skin perfusion in diabetic rats, restoring the blood circulation that is essential for stimulation of these regenerative processes. As seen in the medical literature, it was found that diabetes has caused a slowdown in NCV and latency in rats, which are similar to the early neuropathic changes in diabetic patients. [54, 98, 99] The data demonstrated that ES treatment, especially at 10 mA, could produce profound improvements in NCV and latency in the diabetic rats. [54] Count and density of myelinated axons in the mid-portion of regenerated sciatic nerves showed to be dramatically decreased in the diabetic groups compared to those in the non diabetic normal animals. The vestibulocochlear nerve, a special afferent nerve is also directly affected, perhaps because of its rich vascularization and immense fiber density. Several authors have reported similar results that rats with diabetes usually have a decreased rate of nerve regeneration. [47, 54, 93] However, the reduced regeneration rate after axotomy in diabetes was elevated in the rats as they received ES treatment at 10mA or or above. This improvement is thought to be due to these aforementioned ES's positive effects, i.e., accelerated circulatory blood flow, increased expression of CGRP, or improved macrophage infiltration in the diabetic nerves. [54] We must continue with more studies to try to elucidate several questions still in studies, the experimental model of diabetes only represents the effect of type I diabetes, type 2 diabetes related to feeding and metabolism of carbohydrate is still more compelling still and does not have an experimental model yet .
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